Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258394 | 0.73 | CA4 (0.38) | ALDH1A1TSHRTDP1MAPK1ALOX15 | |
| SCHEMBL2895052 | 0.72 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL3666357 | 0.71 | CA4 (0.36) | ALDH1A1TSHRTDP1ALOX15MAPT | |
| SCHEMBL258348 | 0.71 | CA4 (0.36) | ALDH1A1TSHRTDP1ALOX15MAPT | |
| SCHEMBL258618 | 0.71 | CA4 (0.36) | ALDH1A1TSHRTDP1ALOX15MAPT | |
| SCHEMBL258292 | 0.71 | CA4 (0.36) | ALDH1A1TSHRTDP1ALOX15MAPT | |
| SCHEMBL258478 | 0.71 | CA4 (0.36) | ALDH1A1TSHRTDP1ALOX15MAPT | |
| SCHEMBL30883026 | 0.71 | ELANE (0.42) | ALDH1A1TSHRHSD17B10TDP1MAPT | |
| SCHEMBL2155675 | 0.69 | ALDH1A1 (0.33) | ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL1683358 | 0.69 | MAPK1 (0.33) | ALDH1A1TSHRHSD17B10TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181250-A | Alkenyl phosphine compound and preparation method thereof | 中国石油化工股份有限公司 | 2022-03-15 | — | — | CN | claimed |
| US-6028216-A | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-22 | — | — | US | claimed |
| WO-1999033848-B1 | PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES | GUILFORD PHARM INC (US) | 1999-08-12 | — | — | WO | claimed |
| WO-1999033848-A1 | PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | claimed |
| CN-114181250-A | Alkenyl phosphine compound and preparation method thereof | 中国石油化工股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-107949564-B | Method for producing alkenyl phosphorus compound | 丸善石油化学株式会社 | 2019-11-29 | — | — | CN | disclosed |
| US-10479809-B2 | Method for producing alkenyl phosphorus compound | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2019-11-19 | — | — | US | disclosed |
| US-20190263847-A1 | METHOD FOR PRODUCING ALKENYL PHOSPHORUS COMPOUND | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2019-08-29 | — | — | US | disclosed |
| EP-3348561-A1 | METHOD FOR PRODUCING ALKENYL PHOSPHORUS COMPOUND | Maruzen Petrochemical Co., Ltd. (JP) | 2018-07-18 | — | — | EP | disclosed |
| CN-107949564-A | METHOD FOR PRODUCING ALKENYL PHOSPHORUS COMPOUND | 丸善石油化学株式会社 | 2018-04-20 | — | — | CN | disclosed |
| US-9725552-B2 | HMF-based phenol formaldehyde resin | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-08-08 | — | — | US | disclosed |
| US-20160102165-A1 | HMF-BASED PHENOL FORMALDEHYDE RESIN | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2016-04-14 | — | — | US | disclosed |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS LLC | 2009-06-25 | — | — | US | disclosed |
| US-6028216-A | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999033848-A1 | PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDO1, PPP5C, INMT | ALDH1A1 4061/4885TSHR 4573/4885HSD17B10 3538/4885 |
| US-10479809-B2 | Method for producing alkenyl phosphorus compound | ORC3, OR10J3, ORAI3 | ALDH1A1 1706/4885TSHR 1438/4885HSD17B10 1252/4885 |
| US-20190263847-A1 | METHOD FOR PRODUCING ALKENYL PHOSPHORUS COMPOUND | ORC3, OR10J3, ALK | ALDH1A1 1631/4885TSHR 1162/4885HSD17B10 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.